DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45 th ...

Alkermes plc (NASDAQ:ALKS) just released its annual report and things are looking bullish. It was overall a positive result, with revenues beating expectations by 3.4% to hit US$1.6b. Alkermes ...

Inc. The Alkermes Pathways Research Awards logo is a service mark of Alkermes, Inc. Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and ...

Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 ...

Integrity is a core Alkermes value and the foundation of the way we do business. Alkermes is dedicated to upholding legal, regulatory and ethical standards in the markets in which we operate and ...

Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $33.5 versus the current price of Alkermes at $24.24 ...

Shareholders in Alkermes have quelled a challenge from Sarissa Capital, reelecting seven board members and rejecting three nominees from the activist investor, the Ireland-based drugmaker said.

Alkermes delivered better-than-expected revenue and earnings in the first quarter. The company is encouraged about the early launch of antipsychotic drug Lybalvi. Alkermes reported Q1 revenue of $ ...

Alkermes is drafting a former Major League Baseball player who has struggled with his own alcohol addiction as spokesperson for its alcohol dependency awareness campaign. World Series winner and ...

I get that the transparent logo effect is meant to look cool and minimalist. Jens Thiemer, senior vice president of customer and brand, says it was designed to “radiate more openness and clarity ...

DUBLIN, April 8, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that Jim Robinson, President and Chief Operating Officer, has resigned from his position and will leave the ...

Alkermes (NASDAQ: ALKS) had 2018 revenue that came in at over $1 billion, the level that's typically set as a blockbuster. Of course, it took the biotech a couple of drugs and royalties on a ...